LAS VEGAS--(EON: Enhanced Online News)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) Building on sales to over 50,000 chronic pain sufferers who have tried Quell® since its launch in June 2015, NeuroMetrix announced today that it will unveil innovative upgrades to the company’s 100% drug free wearable pain relief technology at CES 2017 (booth #43421) in Las Vegas.
On Friday January 6, NeuroMetrix President & CEO, Shai N. Gozani, MD, PhD will participate in a panel discussion at The Digital Health Summit at CES. The panel, Digital Health Delivers Personalized Power to the People, will take place, from 2:45-3:15 p.m. (Venetian, Level 4, Lando 4303). The panelists will discuss how digital health tools are giving consumers the power to manage their health and wellness like never before.
About International CES
The International Consumer Electronics Show (International CES) showcases more than 3,800 exhibiting companies, including manufacturers, developers and suppliers of consumer technology hardware, content, technology delivery systems and more; a conference program with more than 300 conference sessions and more than 165K attendees from 150 countries.
For 50 years, CES has been the launch pad for new innovation and technology that has changed the world. Held in Las Vegas every year, it is the world’s gathering place for all who thrive on the business of consumer technologies and where next-generation innovations are introduced to the marketplace.
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief App. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.